Aa
Aa
A
A
A
Close
Avatar universal

Another setback - Arrowhead

PASADENA, Calif.--(BUSINESS WIRE)--
Arrowhead Pharmaceuticals, Inc. (ARWR) is providing an update on its Heparc-2004 clinical study of ARC-520, its therapeutic candidate under clinical investigation for the treatment of chronic hepatitis B virus (HBV) infection. Heparc-2004 is a multicenter, randomized, double-blind, placebo-controlled, multi-dose study of ARC-520, which is currently being performed in up to 12 patients in the United States under an Investigational New Drug (IND).

Arrowhead was notified today verbally by the United States Food & Drug Administration (FDA) of its decision to place a clinical hold on Heparc-2004. The study is on hold while the company provides responses to questions arising from a nonclinical toxicology study in non-human primates using EX1, the company’s liver-targeted, intravenously administered delivery vehicle.
The FDA did not indicate the clinical hold was based on any human findings. To date, EX1 has been administered over 800 times in more than 300 human study subjects and patients. Across this substantial clinical experience, only 3 serious adverse events (SAE) have been observed. Two of these were fevers, treated with acetaminophen, after which the patients continued on the study with no further complications. The other SAE was an instance of hepatic carcinoma in a patient with chronic HBV and cirrhosis, judged by the treating physician to be unrelated to the drug. A small minority (6%) of infusions in ARC-520 studies have been associated with infusion reactions, with 4 patients discontinuing ARC-520 treatment. In addition, across the ARC-520, ARC-521, and ARC-AAT clinical programs, laboratory values have not been deemed indicative of any drug-induced organ toxicity.
Arrowhead has not yet received written notice of the clinical hold from the FDA; however, based on verbal communications the clinical hold was prompted by deaths at the highest dose of an ongoing non-human primate toxicology study. This study involves higher doses of EX1 than those used clinically in humans and higher than those used in the company’s previous animal toxicology studies. The cause of these animal deaths is unknown and under investigation. The EX1 delivery vehicle is used in the company’s ARC-520, ARC-521, and ARC-AAT programs.
3 Responses
Sort by: Helpful Oldest Newest
Avatar universal
& FDA today approved TAF.
Helpful - 1
1 Comments
Thank you royal, this is good news.
VEMLIDY for hbv was approved hours ago by the FDA. We had some more detailed analysis of what this means in terms of side effects and what not.
Avatar universal
Fantastic (TAF)
Helpful - 0
Avatar universal
BENSALEM, Pa.--(BUSINESS WIRE)--
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Arrowhead Pharmaceuticals, Inc. (“Arrowhead” or the “Company”) (NASDAQ: ARWR) concerning the Company and its officers’ possible violations of federal securities laws.

Arrowhead is a biopharmaceutical company that develops novel drugs to treat intractable diseases in the United States.
On November 8, 2016, Arrowhead disclosed that the United States Food & Drug Administration (“FDA”) will be placing a clinical hold on the Company’s Heparc-2004 clinical study of ARC-520. According to Arrowhead, the FDA’s clinical hold is likely due to deaths at the highest dose of an ongoing non-human primate toxicology study.
On this news, Arrowhead stock has fallen as much as 30% during intra-day trading on November 9, 2016.
Helpful - 0
Have an Answer?

You are reading content posted in the Hepatitis B Community

Didn't find the answer you were looking for?
Ask a question
Popular Resources
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.